Bincy Abraham, M.D. Download Headshot

Bincy Abraham, MD, MS

  • Houston Methodist gastroenterologist
  • Inflammatory bowel disease program director, Houston Methodist Hospital Lynda K. and David M. Underwood Center for Digestive Disorders
  • Fondren Distinguished Professor in Inflammatory Bowel Disease, Houston Methodist Hospital Department of Medicine
  • Associate Professor of Clinical Medicine, Houston Methodist Institute for Academic Medicine
Media Contact: Gale Smith , 832.667.5843

Bincy Abraham, MD, MS

Request Interview
Media Contact: Gale Smith , 832.667.5843

Areas of Expertise

  • Capsule endoscopy
  • Clinical Trials
  • Crohn's disease
  • Pregnancy & inflammatory bowel disease
  • Transition of care in inflammatory bowel disease
  • Ulcerative colitis

Credentials

RESIDENCY
University of Texas Medical Branch - Galveston, TX | 2005
INTERNSHIP
University of Texas Medical Branch - Galveston, TX | 2003
MEDICAL SCHOOL
University of Texas Medical Branch at Galveston | 2002
BOARD CERTIFICATION
Gastroenterology | American Board of Internal Medicine
FELLOWSHIP
Gastroenterology - University of Texas Medical Branch - Galveston, TX | 2008

Publications

Role of the industry representative in the practice of gastroenterology and GI endoscopy
ASGE ARIA Committee Chair 2024, , Gastrointestinal Endoscopy, vol. 99, no. 3, pp. 307-313. https://doi.org/10.1016/j.gie.2023.10.057

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series
Thomas, B, Moskow, J, Garza, M, Warren, B, Abraham, B & Glassner, K 2023, , ACG case reports journal, vol. 10, no. 12, pp. e01221. https://doi.org/10.14309/crj.0000000000001221


The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Abraham, BP, Fan, C, Thurston, T, Moskow, J & Malaty, HM 2023, , Nutrients, vol. 15, no. 22, 4847. https://doi.org/10.3390/nu15224847

Real-World Impact of Infliximab Precision-Guided Dosing on Management of Patients With IBD
Abraham, BP, Ziring, DA, Dervieux, T, Han, PA, Shim, A & Battat, R 2023, , American Journal of Managed Care, vol. 29, no. 12 Suppl, pp. S227-S235. https://doi.org/10.37765/AJMC.2023.89447

The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis
Saleh, A, Parsa, S, Garza, M, Quigley, EMM & Abraham, BP 2023, , Digestive Diseases, vol. 41, no. 4, pp. 656-665. https://doi.org/10.1159/000529591

Utility of Intestinal Ultrasound in Clinical Decision-Making for Inflammatory Bowel Disease
Saleh, A & Abraham, BP 2023, , Crohns and Colitis 360, vol. 5, no. 3, otad027, pp. otad027. https://doi.org/10.1093/crocol/otad027

Integrating Intestinal Ultrasound into an Inflammatory Bowel Disease Practice: How to Get Started
Abraham, BP, Reddy, D & Saleh, A 2023, , Crohns and Colitis 360, vol. 5, no. 3, otad043, pp. otad043. https://doi.org/10.1093/crocol/otad043

The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients
Liu, JJ, Abraham, BP, Adamson, P, Barnes, EL, Brister, KA, Damas, OM, Glover, SC, Hooks, K, Ingram, A, Kaplan, GG, Loftus, EV, McGovern, DPB, Narain-Blackwel, M, Odufalu, FD, Quezada, S, Reeves, V, Shen, B, Stappenbeck, TS & Ward, L 2023, , Inflammatory bowel diseases, vol. 29, no. 2, pp. 297-307. https://doi.org/10.1093/ibd/izac124

Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Papamichael, K, Vande Casteele, N, Abraham, BP, Ritter, T, Jain, A & Cheifetz, AS 2023, , Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2022.10.037


Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Papamichael, K, Vande Casteele, N, Abraham, BP, Ritter, T, Jain, A & Cheifetz, AS 2023, , Clinical Gastroenterology and Hepatology, vol. 21, no. 11, pp. 2978-2980.e2. https://doi.org/10.1016/j.cgh.2022.10.037

Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Papamichael, K, Vande Casteele, N, Abraham, BP, Ritter, T, Jain, A & Cheifetz, AS 2023, , Clinical Gastroenterology and Hepatology, vol. 21, no. 11, pp. 2978-2980.e2. https://doi.org/10.1016/j.cgh.2022.10.037


Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults—A population-level analysis in the national health interview survey
Nasir, K, Acquah, I, Dey, AK, Agrawal, T, Hassan, SZ, Glassner, K, Abraham, BP, Quigley, EMM, Blankstein, R, Virani, SS, Blaha, MJ, Valero-Elizondo, J, Cainzos-Achirica, M & Mehta, NN 2022, , American Journal of Preventive Cardiology, vol. 9, 100316. https://doi.org/10.1016/j.ajpc.2022.100316

Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium
Shen, B, Kochhar, GS, Rubin, DT, Kane, SV, Navaneethan, U, Bernstein, CN, Cross, RK, Sugita, A, Schairer, J, Kiran, RP, Fleshner, P, McCormick, JT, DHoore, A, Shah, SA, Farraye, FA, Kariv, R, Liu, X, Rosh, J, Chang, S, Scherl, E, Schwartz, DA, Kotze, PG, Bruining, DH, Philpott, J, Abraham, B, Segal, J, Sedano, R, Kayal, M, Bentley-Hibbert, S, Tarabar, D, El-Hachem, S, Sehgal, P, Picoraro, JA, Vermeire, S, Sandborn, WJ, Silverberg, MS & Pardi, DS 2022, , The Lancet Gastroenterology and Hepatology, vol. 7, no. 1, pp. 69-95. https://doi.org/10.1016/S2468-1253(21)00214-4


Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Alayo, QA, Fenster, M, Altayar, O, Glassner, KL, Llano, E, Clark-Snustad, K, Patel, A, Kwapisz, L, Yarur, AJ, Cohen, BL, Ciorba, MA, Thomas, D, Lee, SD, Loftus, EV, Fudman, DI, Abraham, BP, Colombel, JF & Deepak, P 2022, , Crohns and Colitis 360, vol. 4, no. 1, otac002, pp. otac002. https://doi.org/10.1093/crocol/otac002

Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician
Saleh, A, Ansari, U, Abughazaleh, S, Glassner, K & Abraham, BP 2022, , Biologics: Targets and Therapy, vol. 16, pp. 67-83. https://doi.org/10.2147/BTT.S335697

P013 Resolution of Infliximab Associated Infusion Hypersensitivity After Switching to Biosimilar Infliximab-dyyb
Malcolm, I, Rosalind, B, Heather, L & Bincy, A 2021, , The American Journal of Gastroenterology, vol. 116, pp. S3. https://doi.org/10.14309/01.ajg.0000798652.07957.ee

Languages

English